DiscoveryProbe™ FDA-approved Drug Library: Mechanisms, Applications, and Evidence

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (L1021) comprises 2,320 bioactive compounds approved by agencies such as FDA, EMA, HMA, CFDA, and PMDA, supporting rapid drug repositioning and target identification in diverse disease models [1]. Each compound's mechanism—ranging from receptor modulation to enzyme inhibition—is well characterized and documented [2]. The library is provided as 10 mM DMSO solutions in multiple HTS/HCS-compatible formats, with 12-month stability at -20°C and up to 24 months at -80°C. Its standardized, machine-readable design facilitates integration into automated screening workflows. APExBIO ensures regulatory traceability and compound provenance for all entries.

Biological Rationale

Polypharmacy is increasingly common, with patients often prescribed multiple drugs concurrently. This raises the risk of drug-drug interactions, many of which are mediated by cytochrome P450 (CYP) enzymes, especially CYP3A4 and CYP3A5, responsible for metabolizing the majority of approved drugs (DOI:10.1038/s41467-025-58749-8). As a result, understanding drug metabolism and interaction profiles is essential in preclinical and translational research. Comprehensive, clinically relevant compound libraries enable systematic study of these processes using high-throughput and high-content screening methodologies. The DiscoveryProbe™ FDA-approved Drug Library is designed to address these needs, supporting the discovery of novel pharmacological mechanisms and facilitating safer, more effective therapeutic development (see related analysis—this article further details mechanistic diversity and screening parameters).

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The library includes drugs with well-characterized mechanisms, such as receptor agonists, receptor antagonists, enzyme inhibitors, ion channel modulators, and signal pathway regulators. Representative compounds include doxorubicin (DNA intercalator, topoisomerase II inhibitor), metformin (AMPK activator), and atorvastatin (HMG-CoA reductase inhibitor). Many compounds act on signaling pathways relevant to cancer, metabolic, infectious, and neurodegenerative diseases. For example, CYP3A4 modulators are present, enabling direct study of drug metabolism and interaction mechanisms (Wang et al., 2025). The inclusion of approved drugs with diverse mechanisms facilitates the identification of off-target effects, repurposing opportunities, and synergistic or antagonistic interactions in complex biological systems. The compounds are dissolved at 10 mM in DMSO, compatible with most cell-based and biochemical assays.

Evidence & Benchmarks

• The DiscoveryProbe™ FDA-approved Drug Library comprises 2,320 compounds, each approved by at least one major regulatory agency or listed in authoritative pharmacopeias (APExBIO product page).
• Compounds span a wide range of mechanisms, including receptor modulation, enzyme inhibition, and ion channel regulation (Wang et al., 2025).
• High-throughput screening using this library has enabled the discovery of selective CYP3A4 inhibitors, highlighting its utility in uncovering mechanistic selectivity among closely related drug targets (Wang et al., 2025).
• All compounds are supplied as 10 mM DMSO solutions, with validated stability for 12 months at -20°C and 24 months at -80°C (APExBIO).
• Screening formats include 96-well plates, deep well plates, and 2D barcoded screw-top tubes, supporting integration into automated platforms (related review—here, we detail compound stability and regulatory traceability).
• Machine-readable inventory and compound annotation files are provided, supporting data integration and bioinformatic analyses (library overview—this article expands on HTS/HCS workflows and evidence of utility).

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library is used in:

• Drug repositioning screening: Rapidly identifies new indications for approved drugs (see prior benchmark—this article covers updated stability and mechanistic coverage).
• Pharmacological target identification: Uncovers new molecular targets and pathways.
• Cancer research drug screening: Identifies compounds modulating oncogenic pathways.
• Neurodegenerative disease drug discovery: Screens for modulators of neuronal signaling and protein aggregation.
• Signal pathway regulation studies: Dissects signaling networks using well-annotated mechanism-of-action compounds.
• Enzyme inhibitor screening: Assesses specificity/selectivity for key enzymes such as CYP3A4 and CYP3A5 (Wang et al., 2025).

Common Pitfalls or Misconceptions

• The library is not exhaustive for all approved drugs worldwide; inclusion criteria are based on regulatory agency approval or pharmacopeial listing.
• Not all compounds are suitable for in vivo administration; pre-dissolved in DMSO, they are intended for screening, not direct clinical use.
• Synergistic or antagonistic effects observed in screening require secondary validation in more complex models.
• Not intended for use as a primary chemical probe collection for novel bioactivity—focus is on approved, characterized entities.
• Mechanistic annotations rely on current literature and may be updated as new data emerges.

Workflow Integration & Parameters

The DiscoveryProbe™ FDA-approved Drug Library is optimized for streamlined integration into automated high-throughput and high-content screening systems. Compounds are delivered as 10 mM DMSO solutions, compatible with acoustic dispensing and liquid handling robots. Available formats include 96-well and deep-well microplates, as well as individually barcoded screw-top tubes for flexible storage and retrieval. Inventory and annotation files are provided in CSV/XLSX formats, supporting direct import into electronic lab notebooks and cheminformatics platforms. APExBIO recommends storage at -20°C (12 months stability) or -80°C (24 months stability) with minimal freeze-thaw cycles. Shipping can be tailored (blue ice or ambient) to user requirements. Researchers are encouraged to validate compound identity and concentration prior to critical screens. The library supports integration with phenotypic assay pipelines, CRISPR screens, and multi-omics data workflows (see mechanistic synergy article—this article adds new guidance on HTS/HCS compatibility and storage best practices).

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library (L1021) from APExBIO represents a robust, well-curated resource for rapid, mechanism-focused drug discovery. Its breadth of regulatory coverage, mechanistic diversity, and standardized format enable high-throughput and high-content applications in oncology, neurology, pharmacology, and beyond. Ongoing advances in screening technologies and informatics will further enhance the value of such libraries in translational research—enabling safer, more effective therapies through rational drug repositioning and target validation. For detailed product specifications and ordering, refer to the DiscoveryProbe™ FDA-approved Drug Library page.